Company Overview of Oxford BioTherapeutics Limited
Oxford BioTherapeutics Limited is engaged in the development of antibody-based cancer drugs for the treatment of cancer. It offers therapeutic antibodies and diagnostics. The company also provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies. It has strategic partnerships with Seattle Genetics Inc., Medarex Inc., Biosite Inc., Amgen Inc., and GlaxoSmithKline; and a strategic alliance with A. Menarini Industrie Farmaceutiche Riunite Srl. Oxford BioTherapeutics Limited was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Limited. in December 2008. The company was incorporated in 2003 and ...
94a Milton Park
Oxon, OX14 4RY
Founded in 2003
Key Executives for Oxford BioTherapeutics Limited
Chief Operations Officer and Executive Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Head of Clinical Development
Compensation as of Fiscal Year 2014.
Oxford BioTherapeutics Limited Key Developments
Oxford BioTherapeutics Appoints Eugen Leo as Head of Clinical Development
Jul 8 14
Oxford BioTherapeutics announced the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research experience, and will be responsible for driving the Company's attractive pipeline of ADCs into clinical development. He previously worked at Micromet, where he held several positions with increasing seniority and was instrumental in developing the company's BiTE antibody platform to clinical proof-of-concept, which received breakthrough therapy designation by FDA on July 1, 2014.
Oxford BioTherapeutics Appoints Keith E Wilson as Chief Scientific Officer
Jun 18 14
Oxford BioTherapeutics announced the appointment of Dr. Keith E Wilson as Chief Scientific Officer. Dr. Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates. Dr. Keith E Wilson brings to Oxford BioTherapeutics over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, as well as providing executive-level support for corporate and business development activities. In his most recent role, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team.
Oxford BioTherapeutics Limited Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014
Mar 21 14
Oxford BioTherapeutics Limited Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|